



Biotech Daily

Tuesday May 21, 2019

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: LBT UP 136%; ACTINOGEN DOWN 7%**
- * **CARDIEX BUSINESS, MARKETING OPERATIONS IN CHINA**
- * **ADALTA REQUESTS CAPITAL RAISING TRADING HALT**
- * **CELLMID BUYS BACK 499k UNMARKETABLE PARCEL SHARES**
- * **ADMEDUS REQUESTS 3rd FUNDING SUSPENSION EXTENSION**
- * **'BANK OF NEW YORK MELLON' TAKES 26% OF AVITA**
- * **MACQUARIE TAKES 5% OF IMPEDIMED, AGAIN**
- * **MORGAN STANLEY TAKES 7% OF TOTAL BRAIN**

MARKET REPORT

The Australian stock market was up 0.37 percent on Tuesday May 21, 2019, with the ASX200 up 24.0 points to 6,500.1 points.

Fourteen of the Biotech Daily Top 40 stocks were up, 19 fell, three traded unchanged and four were untraded.

LBT was the best on last night's news of FDA approval for its APAS Independence, up 9.5 cents or 135.7 percent to 16.5 cents, with 69.9 million shares traded.

Antisense climbed six percent; Imugene was up 5.9 percent; Benitec improved four percent; Immutep and Oncosil were up more than three percent; Avita, Compumedics, Pharmaxis, Telix and Volpara rose two percent or more; Cyclopharm was up 1.6 percent; with Cochlear, Cynata and Neuren up by less than one percent.

Actinogen led the falls, down 0.1 cents or 6.7 percent to 1.4 cents, with 4.3 million shares traded followed by Opthea down 6.4 percent to 66 cents with 128,994 shares traded.

Nanosonics, Optiscan and Universal Biosensors fell more than four percent; Clinuvel, Optiscan and Proteomics lost more than three percent; Impedimed, Orthocell, Paradigm, Polynovo, Prescient and Pro Medicus shed more than two percent; Dimerix, Ellex and Mesoblast were down more than one percent; with CSL, Medical Developments, Resmed and Starpharma down by less than one percent.

CARDIEX

Cardiex says it has established a business and marketing operation in Beijing and Shanghai to support its business initiatives in China.

Cardiex said it had begun hiring operations, business and marketing employees who would report to head of corporate development Zihan Lin.

The company recently said that the Chinese Food and Drug Administration had approved its Oscar 2 with Sphygmocor inside ambulatory blood pressure monitor, developed with the Morrisville, North Carolina-based Suntech Medical (BD: Apr 23, 2019).

Cardiex fell 0.1 cents or 2.6 percent to 3.7 cents with 4.9 million shares traded.

ADALTA

Adalta has requested a trading halt "pending an announcement of a capital raising".

Trading will resume on May 23, 2019 or on an earlier announcement.

Adalta last traded at 18.5 cents.

CELLMID

Cellmid says it has bought-back 499,117 shares at 23 cents a share, spending \$114,797 on its unmarketable share parcel facility.

Cellmid said it bought the shares from 558 holders, who held parcels worth \$500 or less and composing 28.9 percent of total shareholders.

The company said the shares would be cancelled following the transfer.

Cellmid said that shareholders with unmarketable parcels would not incur brokerage fee and that costs associated with maintaining a larger share register would be reduced.

Cellmid fell half a cent or 2.6 percent to 19 cents.

ADMEDUS

Admedus has requested a further extension to its voluntary suspension to finalize its recapitalization plan on May 7, 2019.

In April, Admedus requested a trading halt "pending an announcement regarding the ... immunotherapies sale transaction" and later requested a voluntary suspension for the sale of Admedus Vaccines, formerly Coridon (BD: Apr 15, 17, 2019).

On April 23, the company responded to an ASX aware query, announced the termination of the Vaccine business sale and requested an extension to the suspension "to finalize the ... recapitalization plan" (BD: Apr 23, 2019).

Earlier this month, the company requested a further extension to the voluntary suspension saying it expected to last until May 21, 2019 (BD: May 7, 2019.)

Today, the company requested a further extension to the suspension which it expected to last until June 4, 2019 or the release of an earlier announcement.

Admedus last traded at six cents.

AVITA MEDICAL

The Bank of New York Mellon Corp says it has increased its substantial shareholding in Avita from 469,774,920 shares (25.20%) to 488,880,800 shares (26.22%).

The Bank of New York Mellon said that between May 7 and 17, 2019, it was subject to the "deposit of securities" and "transfer out of securities" at no cost or financial return.

Avita was up one cent or 2.1 percent to 48 cents with 9.2 million shares traded.

IMPEDIMED

The Sydney-based Macquarie Group and related parties say they have become substantial shareholders in Impedimed with 19,041,569 shares or 5.01 percent. Macquarie Group said that in 64 trades between March 20 and May 7, 2019 it bought, sold, borrowed, returned and transferred shares at prices between 20 cents and 29 cents; and in more than 1,500 individual trades between May 7 and May 10, 2019 it bought shares at 22 cents a share.

In 2017, Macquarie Group said it had become substantial in Impedimed with 20,647,529 shares (5.50%), buying shares at prices ranging from 57 cents to 85 cents, ceasing its substantial holding in July 2017 (BD: Jun 30, Jul 11, 2017).

In 2018, Macquarie Group said it bought Impedimed shares at prices ranging from 35 cents to 46 cents, ceasing its substantial holding in March 2019 (BD: Aug 13, 2018).

Impedimed fell half a cent or 2.3 percent to 20.5 cents.

TOTAL BRAIN

Morgan Stanley and subsidiaries say they have become substantial shareholders in Total Brain with 52,754,460 shares or 6.78 percent.

Morgan Stanley said it bought 25,900,000 shares on May 16, 2019 for \$701,890 or 2.7 cents a share.

Total Brain fell 0.1 cents or 3.6 percent to 2.7 cents with 48.7 million shares traded.